Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

126.76 +2.46 (+1.98%)
Streaming Delayed Price Updated: 3:49 PM EDT, Jun 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
75 76 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
News headline image
5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call
Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the... 
Via StockStory
Topics Earnings Intellectual Property World Trade
News headline image
The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
News headline image
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag ↗
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price. 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering ↗
GILEAD SCIENCES INC (NASDAQ:GILD) is a quality stock with strong profitability, high ROIC, and reasonable valuation, making it a candidate for long-term investors. 
Via Chartmill
News headline image
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention ↗
Analysts at Oppenheimer, BMO, Morgan Stanley, and Mizuho weighed in with positive long-term views, though Oppenheimer flagged near-term headwinds tied to court risks and cannibalization of existing... 
Via Stocktwits
News headline image
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug ↗
The drug will sell under the brand name Yeztugo. In clinical testing, it kept 99.9% of patients from contracting HIV. 
Via Investor's Business Daily
News headline image
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
From Gilead Sciences, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report ↗
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising concerns over global access and equity. 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A potential undervalued opportunity in biopharma ↗
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability and reasonable growth, making it a candidate for value investors. The stock trades below industry averages on key valuation... 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
News headline image
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
Why Gilead Scinces Stock Tumbled on Tuesday ↗
Via The Motley Fool
News headline image
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes ↗
The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. 
Via Stocktwits
News headline image
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence ↗
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of... 
Via Stocktwits
News headline image
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may... 
Via StockStory
Topics Stocks
News headline image
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug ↗
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035. 
Via Benzinga
News headline image
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
News headline image
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating ↗
The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. 
Via Stocktwits
News headline image
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance ↗
Gilead Chief Commercial Officer Johanna Mercier told Reuters that the company is eyeing a “global approach" to the launch of Lenacapavir. 
Via Stocktwits
Topics Government
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering ↗
GILEAD SCIENCES (NASDAQ:GILD) is a high-quality biopharma stock with strong profitability, efficient capital use, and attractive valuation, making it a candidate for long-term investors. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock ↗
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors. 
Via Chartmill
News headline image
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.